Infective endocarditis (IE) and sternal wound infections (SWI) following heart surgery are severe diseases associated with high rates of mortality and significant morbidity 1 . IE and SWI are most often caused by gram-positive organisms. Vancomycin is the standard therapy but it has been associated with a risk of renal failure and suboptimal outcomes, leading to the need of alternative antimicrobial agents 2, 3 . In this retrospective study (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) , we reviewed the prescriptions of daptomycin in a
French tertiary-care referral center for IE and SWI to assess the safety and outcomes among patients treated with high-dose daptomycin (HDD). We defined HDD as the use of daptomycin at a dose superior to 6 mg/kg/day in patients with normal renal function 4 Creatine kinase (CK) was measured at baseline and followed in 77% of patients (n=55). Only 3 patients (5%) presented a CK increase compatible with muscle toxicity after 1 week of daptomycin at a respective dose of 10.4 mg/kg/day, 10 mg/kg/day and 8 mg/kg/day. The first patient had a CK increase (from 26 to 1036 IU/mL over 3 weeks) and an acute kidney injury whilst on daptomycin. He presented concomitantly a hemorrhagic colitis complicated by hypovolemic shock, multiple organ failure and death. The second patient developed a septic shock due to a urinary tract infection in the UCI. The third patient had a superficial SWI with no concomitant etiology of CK increase. CK increased from 13 IU/mL to 2836 IU/mL after 2 weeks of daptomycin, with no muscle symptoms nor modification of blood creatinine. As the planned duration of antibiotic therapy was 2 weeks, daptomycin was stopped after completion of therapy, followed by a progressive normalization of CK values.
Daptomycin was prematurely discontinued, replaced by vancomycin due to a suspected AE in 3 patients. The first patient was the one who died of a hemorrhagic colitis. The second patient had an unexplained fever that stopped after the discontinuation of daptomycin. The third patient presented unexplained thrombocytopenia, daptomycin and proton-pump inhibitors were stopped, followed by a normalization of platelet values.
This observational study of 71 patients with severe infections and comorbidities adds to the evidence that HDD is effective and well-tolerated in both IE and SWI. Whether daptomycin should be considered as a first-line therapy in patients with severe gram-positive heart or mediastinal infections remains to be determined with the help of randomized controlled trials. 
